ImmuCell Corporation (ICCC)
ICCC trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/811641/000143774926010339/0001437749-26-010339-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ICCC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 1987 |
| SEC CIK | 0000811641 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $27.6M |
| Net income | -$1.0M |
| Operating income | $1.6M |
| Net margin | -3.8% |
| Operating margin | 6.0% |
| Revenue growth | +4.3% |
| Cash | $3.8M |
| Total assets | $42.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $7.9M cash; operating cash flow $2.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 9,091,361 (2026-10-30); 9,045,851 a year earlier; 7,750,864 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Wipfli LLP, Radnor, Pennsylvania, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $172K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $8.0M | $953K | $756K | $7.9M | $7.9M | $33.2M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $7.2M | $1.8M | $3.0M | $8.9M | $8.3M | $30.7M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $10.4M | $1.9M | $3.6M | $6.8M | $8.7M | $29.9M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $7.6M | -$2.8M | $483K | $3.8M | $9.1M | $27.6M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $5.5M | -$140K | -$1.2M | $3.9M | $9.5M | $27.8M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $6.4M | $502K | $1.6M | $6.0M | $9.8M | $28.3M | 10-Q 2025-08-14 |
| Q1 2025 2025-03-31 | $8.1M | $1.4M | $1.6M | $4.6M | $10.2M | $27.3M | 10-Q 2025-05-14 |
| Q4 2024 2024-12-31 | $7.8M | $515K | -$3K | $3.8M | $10.5M | $26.5M | 10-K 2025-03-28 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B2 | 2024-04-10 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-05-13 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-13 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 799 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +9.7% |
| 1 month | -0.4% |
| 3 months | -1.4% |
| Year to date | +74.8% |
| 1 year | +77.7% |
| From 52-week high | -8.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMDX | Insight Molecular Diagnostics Inc. | $1.86 | -13.08% | $60.9M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
| MYGN | Myriad Genetics Inc. | $5.57 | -1.59% | $534.3M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| VNRX | VolitionRX Limited | $0.1998 | -13.13% | $7.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier